Crucell
Booster shot 'improves TB resistance in previously vaccinated adults'
...with the vaccine''s action. The Aeras-402 vaccine, developed by Aeras Global Tuberculosis Foundation and Crucell, was made by weakening the virus in the lab, so that it can no longer...
New TB booster shows promise
...with the vaccine's action. The Aeras-402 vaccine, developed by Aeras Global Tuberculosis Foundation and Crucell, was made by weakening the virus in the lab, so that it can no longer...
JavaScript and Flash are required to fully enjoy Evri
FACTBOX-Top biotech takeout targets of 2010 -Morningstar
...$1.3 billion 5) Celgene, $28.3 billion 6) Exelixis, $730 million 7) Genzyme, $15.2 billion 8) Crucell, $1.7 billion 9) Elan, $4.2 billion 10) BioMarin, $2.3 billion...
UPDATE 2-Intercell Q4, outlook disappoint, shares slide
...said in a note. Intercell, the only major independent vaccine maker left in Europe aside from Dutch company Crucell <CRCL.AS>, last year started to sell Ixiaro, distributed with Swiss...
Crucell Beefs Up R&D
by: The Burrill Report February 14, 2010 | about: CRXL Crucell (CRXL), the Dutch vaccine maker, will bolster its research and development spending in 2010 by more than one third, or about...
Crucell N.V. ADS Q4 2009 Earnings Call Transcript
...- VP, Corporate Communications & IR Operator Good afternoon, ladies and gentlemen and welcome to the Crucell fourth quarter and full year 2009 result conference call. My name is Dave...
UPDATE 4-Crucell seeking new growth engine, to boost R&D
...but beating the average forecast of 9 million ($12 million) from a Reuters poll of six analysts. Crucell <CRXL.O> had a restated net profit of 18.9 million euros in the same period in...
Ebola, Marburg vaccines undergoing tests in S.A.
...is undergoing tests at Southwest Foundation for Biomedical Research. The Dutch pharmaceutical company Crucell, which developed the vaccine under a $30 million contract with the...
"We need better management of the available resources for immunization, human resources, technologies and we need increased funding to improve the capacity of governments to purchase vaccines and we need also greater mobilization of people," Dr. Sambo said. "We need to inform people ... to bring their people to vaccination campaigns" (12/14). In related news, the pharmaceutical company Crucell "will likely look to add a sixth antigen" to its Quinvaxem vaccine, a mix of vaccines against five childhood diseases" in an effort to maintain the company's market position, which is coming under pressure," Reuters reports. "'We are working on an hexavalent vaccine but for competitive reasons we are not mentioning what the sixth antigen will be,' Crucell spokeswoman Oya Yavuz said in a recent e-mail interview. Despite Crucell's reluctance to reveal what antigen it will acquire, the World Health Organisation said polio is likely to be added in future to the pentavalent paediatric vaccines bought by UNICEF, forming an hexavalent vaccine"
Wild Poliovirus Reaches More African Countries In 2009, WHO Official Says Medical News Today | 3 months ago
Wild Poliovirus Reaches More African Countries In 2009, WHO Official Says
...... to bring their people to vaccination campaigns" (12/14). In related news, the pharmaceutical company Crucell "will likely look to add a sixth antigen" to its Quinvaxem vaccine, a...
UPDATE 1-Crucell Q3 profit falls 22 pct, keeps outlook
...Q3 net profit 10 mln euros vs 12 mln expected (Adds CEO comment, detail) Dutch biotech firm Crucell <CRCL.AS> <CRXL.O> reiterated its full-year revenue outlook despite reporting...
Crucell deal forms base of J&J vaccine platform
...at Johnson & Johnson said he hopes the company's $444 million investment this week in Dutch biotech company Crucell will bring about a major shift in the way influenza is treated. "We...
J&J acquires 18% in Crucell
...aEUR" often at distressed prices due to the economic downturn. Crucell said it issued 14.6 million new Crucell shares to Johnson & Johnson, which paid about a 30% premium based...
